Skip to main navigation
Skip to search
Skip to main content

Research Profiles at Washington University School of Medicine Home

Help & FAQ

Home
Profiles
Departments, Divisions and Centers
Research output

Search by expertise, name or affiliation

Lorlatinib: a new-generation drug for ALK-positive NSCLC

Saiama N. Waqar, Daniel Morgensztern

Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center

Research output: Contribution to journal › Comment/debate

12 Scopus citations

Overview
Fingerprint

Fingerprint

Dive into the research topics of 'Lorlatinib: a new-generation drug for ALK-positive NSCLC'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Powered by Pure, Scopus & Elsevier Fingerprint Engine™

All content on this site: Copyright © 2025 Research Profiles at Washington University School of Medicine, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply

We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies

About web accessibility

Report vulnerability